Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Pharm Sci. 2021 Feb 5;110(4):1572–1582. doi: 10.1016/j.xphs.2021.02.003

Table 6.

Comparison of clinical trials data in plaque psoriasis patients based on full-analysis (FAS) results, except for Idacio® where per protocol set (PPS) data was reported for primary outcomes.

Product Study Name Study Population Treatment Duration PASI 75 Response Rate (Week 16) ADA Positive (Week 16)
Amgevita™ 20120263 ABP501: N=175
Humira®: N=175		 Main phase: 16 w
Total: 52 w		 ABP 501: 74.4%
Humira®: 82.7%		 ABP 501: 55.2%
Humira®: 63.6%
Hyrimoz™ GP2017–301 GP2017: N=231
Humira®: N=234		 Main phase: 16 w
Total: 51 w		 GP2017:58.1%
Humira®: 55.9%		 GP2017:25.7%
Humira®: 23.6%
Idacio® EMR200588–002 MSB11022: N=202
Humira®:N=189		 Main phase: 16 w
Total: 54 w		 MSB11022: 90.0%
Humira®: 92.0%		 MSB11022: 89.1%
Humira®: 90.9%